# A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Study · id `cardio:ct-nct01347710` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01347710](<https://clinicaltrials.gov/study/NCT01347710>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01347710

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 795 participants.

## Technical summary

Registry record NCT01347710. Allocation not applicable; no masking; primary purpose diagnostic. Start 2011-06 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2016-04-05.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 795 participants (enrolled count; ClinicalTrials.gov record NCT01347710, source copy `cardio:ctgov-nct01347710-2020-11-24`, retrieved 2026-10-26)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT01347710, source copy `cardio:ctgov-nct01347710-2020-11-24`, retrieved 2026-10-26)
- Primary completion: 2013-07 (actual) (ClinicalTrials.gov record NCT01347710, source copy `cardio:ctgov-nct01347710-2020-11-24`, retrieved 2026-10-26)
- Completion: 2013-09 (actual) (ClinicalTrials.gov record NCT01347710, source copy `cardio:ctgov-nct01347710-2020-11-24`, retrieved 2026-10-26)
- Results first posted: 2016-04-05 (ClinicalTrials.gov record NCT01347710, source copy `cardio:ctgov-nct01347710-2020-11-24`, retrieved 2026-10-26)
- Countries: United States; Canada; Finland; Puerto Rico (ClinicalTrials.gov record NCT01347710, source copy `cardio:ctgov-nct01347710-2020-11-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01347710-2020-11-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
- Condition: Coronary Artery Disease
- Intervention (Drug): Flurpiridaz F18
- Intervention (Drug): 99mTechnicium (sestamibi or tetrofosmin)
- Lead sponsor: Lantheus Medical Imaging
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease (`cardio:pubmed-32703509`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Utility of 18F-Flurpiridaz PET Relative Flow Reserve in Differentiating Obstructive From Nonobstructive Coronary Artery Disease (`cardio:pubmed-41064867`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: eff117d7b51bc840dc220baec3cda35a76841438edb27ea44c509a8a8eee68e1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
